The CSL Limited (ASX: CSL) share price is backtracking 1.24% to $292.73 today following the release of the company's full-year results.
The biotherapeutics company reported a mixed performance due to a "difficult global environment."
Nonetheless, the result was in line with expectations, achieving the top end of its guidance.
Here's a look at the CSL's latest dividend that was announced to the market.
CSL maintains full-year dividend
After delivering a net profit after tax (NPAT) of $2,255 million in FY22, the CSL board declared a final dividend of US$1.18 per share.
When converted to the Australian currency, this reflects an approximate dividend of $1.68 per share, franked at 10%.
Moreover, despite CSL maintaining its full-year dividend of US$2.22 apiece, this is 6% higher due to favourable currency movements.
The full-year dividend is equivalent to 46.2% of the group's basic earnings per share (EPS) of US$4.81.
You still have time to scoop up the latest dividend as the ex-dividend date falls on 6 September.
CSL will pay the distribution of its profits to eligible shareholders on 5 October.
What about the FY23 dividend?
While CSL didn't give any guidance on its dividend for FY23, we take a look at what Goldman Sachs had to say.
The broker released its key takeaways on the back of CSL's FY22 results.
It said "NPAT is guided to $2.4bn-2.5bn, excluding Vifor (constant currency terms). Consensus expectations are heavily distorted by the impact of Vifor in our view, but our best guess at 'organic CSL' consensus is $2.575bn."
Upside risks included: More supportive pricing dynamic than we already expect, positive results from pipeline/pre-commercialisation products, and plasma donor fee deflation.
However, downside risks involved: Competitive product launches, challenges associated with unemployment/payer mix, and sustained challenges due to COVID-19.
Goldman Sachs has a neutral rating on CSL with a 12-month target price of $307 per share.
CSL share price snapshot
Over the last 12 months, the CSL share price experienced volatility on the back of an uncertain global economic outlook.
After touching a 52-week low of $240.10 on 15 February, its shares hit resistance at around the $270 mark.
Since then, that barrier has been breached with CSL shares trading around 4% under the psychological $300 level.
Based on today's price, CSL commands a market capitalisation of $141 billion and has a trailing dividend yield of 1.03%.
